ReviewCurrent gastroenterology reports2018
Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders.
Review in Current gastroenterology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Anxiety and depression in Indian patients with irritable bowel syndrome: A meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Pooled it
- Dissecting pleiotropy between major depressive disorder and physical disease comorbidities.Nature genetics · 2026Article
- Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: 'Auckland Classification' v1.0.Neurogastroenterology and motility · 2026Article
- Low-Frequency Electroacupuncture versus Sham Electroacupuncture for Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Ganhai Weikang Capsules ameliorate functional dyspepsia in rats by modulating gut microbiota and host metabolic homeostasis.Frontiers in pharmacology · 2026Article
- Insights Into Functional Dyspepsia and Gastroparesis - Western Versus Asian Perspectives.Journal of neurogastroenterology and motility · 2025Review
- Prevalence, types, and risk factors of functional gastrointestinal diseases in Hainan Province, China.Scientific reports · 2024Article
- Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study.Journal of neurogastroenterology and motility · 2024Article
- Virtual Reality: A New Treatment Paradigm for Disorders of Gut-Brain Interaction?Gastroenterology & hepatology · 2023Article
- Comparison of the potency of nortriptyline and mirtazapine on gastrointestinal symptoms, the level of anxiety and depression in patients with functional dyspepsia.Gastroenterology and hepatology from bed to bench · 2023Article
- Comparing the efficacy of duloxetine and nortriptyline in alleviating the symptoms of functional dyspepsia - a randomized clinical trial.Frontiers in psychiatry · 2023Article
- Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders.Frontiers in pharmacology · 2023Article
- Review
- Review
- Depression and Pain: Use of Antidepressants.Current neuropharmacology · 2022Review
- Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.Frontiers in pharmacology · 2022Review
- Special Considerations for the Management of Disorders of Gut-Brain Interaction in Older Adults.Current treatment options in gastroenterology · 2022Review
- Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population.United European gastroenterology journal · 2021Article
- MODERN APPROACH TO DYSPEPSIA.Acta clinica Croatica · 2021Review
- The Impact of COVID-19 Pandemic on Neurogastroenterologists in Latin America: Results of an Online Survey.Journal of clinical gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe functional gastrointestinal disorders, or disorders of gut-brain interaction as defined by the Rome IV criteria, are the most common diagnostic entities in gastroenterology. Treatments that address the dysregulation of gut-brain interaction with these disorders are increasingly gaining interest as a better option than for example traditional analgesics, particularly opioids. Antidepressants, antianxiety and antipsychotic medications, and visceral analgesics, now termed neuromodulators, are included in this update addressing the evidence of treatment benefit in disorders of brain-gut interaction. RECENT
findingsBy a careful selection based on a multidimensional clinical profile, a decreased symptom burden, particularly regarding abdominal pain, nausea, and vomiting, as well as improved social function and quality of life, can be obtained by use of neuromodulators. There is good evidence for the peripheral neuromodulators from studies in bowel disorders, and the central neuromodulators both from indirect evidence in chronic pain disorders as well as selected disorders of brain-gut interaction. Basic knowledge about the pharmacologic properties and clinical use of neuromodulators in disorders of brain-gut interaction improves the treatment outcome and avoids use of traditional analgesics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.